Rigel Pharmaceuticals Management
Management criteria checks 3/4
Rigel Pharmaceuticals' CEO is Raul Rodriguez, appointed in May 2010, has a tenure of 14.58 years. total yearly compensation is $3.44M, comprised of 21.2% salary and 78.8% bonuses, including company stock and options. directly owns 0.74% of the company’s shares, worth $2.16M. The average tenure of the management team and the board of directors is 3.6 years and 6.4 years respectively.
Key information
Raul Rodriguez
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 21.2% |
| CEO tenure | 14.6yrs |
| CEO ownership | 0.7% |
| Management average tenure | 3.6yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop
Dec 20
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Nov 08Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Oct 10Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth
Sep 25There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise
Jul 30Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
Jul 24Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding
May 01Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Mar 04Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
Feb 23Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S
Jan 15Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?
Oct 25Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib
Oct 10Rigel Pharma adds ~7% to reach over two month high
Aug 18Rigel rises 17% on strong Q2 result
Aug 03Rigel Pharmaceuticals: A Status Check
May 31Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Apr 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$4m |
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$20m |
| Dec 31 2023 | US$3m | US$728k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$3m | US$700k | -US$59m |
| Sep 30 2022 | n/a | n/a | -US$83m |
| Jun 30 2022 | n/a | n/a | -US$85m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | US$3m | US$662k | -US$18m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$3m | US$662k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$3m | US$649k | -US$67m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$59m |
| Mar 31 2019 | n/a | n/a | -US$64m |
| Dec 31 2018 | US$4m | US$637k | -US$70m |
| Sep 30 2018 | n/a | n/a | -US$100m |
| Jun 30 2018 | n/a | n/a | -US$93m |
| Mar 31 2018 | n/a | n/a | -US$87m |
| Dec 31 2017 | US$2m | US$618k | -US$78m |
Compensation vs Market: Raul's total compensation ($USD3.44M) is above average for companies of similar size in the US market ($USD1.38M).
Compensation vs Earnings: Raul's compensation has been consistent with company performance over the past year.
CEO
Raul Rodriguez (63 yo)
14.6yrs
Tenure
US$3,440,790
Compensation
Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 14.6yrs | US$3.44m | 0.74% $ 2.2m | |
| Executive VP & CFO | 6.6yrs | US$1.21m | 0.069% $ 200.0k | |
| Executive VP | 2yrs | US$683.00k | 0.0028% $ 8.2k | |
| Executive VP & Chief Commercial Officer | 4.3yrs | US$1.34m | 0.031% $ 90.6k | |
| Senior VP of Human Resources | 2.9yrs | no data | no data | |
| Executive Vice President of Research | 8.3yrs | US$796.09k | no data | |
| Executive VP & Chief Business Officer | less than a year | no data | no data | |
| Executive VP & Chief Medical Officer | less than a year | no data | no data | |
| Vice President of Marketing | no data | no data | no data |
3.6yrs
Average Tenure
61yo
Average Age
Experienced Management: RIGL's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.1yrs | US$3.44m | 0.74% $ 2.2m | |
| Independent Director | 27.8yrs | US$138.58k | 0.044% $ 127.0k | |
| Independent Director | 5.8yrs | US$145.58k | 0.043% $ 123.3k | |
| Independent Chairman of the Board | 7.1yrs | US$190.58k | 0.043% $ 123.3k | |
| Independent Director | 3yrs | US$140.58k | 0.025% $ 71.9k | |
| Independent Director | 3.6yrs | US$212.98k | 0.032% $ 92.5k |
6.4yrs
Average Tenure
65yo
Average Age
Experienced Board: RIGL's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:31 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rigel Pharmaceuticals, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | Barclays |
| Clarence Powell | BMO Capital Markets Equity Research |
| James Birchenough | BMO Capital Markets Equity Research |